Free Trial

Fulcrum Therapeutics (FULC) Stock Forecast & Price Target

Fulcrum Therapeutics logo
$3.32
+0.06 (+1.84%)
(As of 11/5/2024 ET)

Fulcrum Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
6
Buy
3

Based on 10 Wall Street analysts who have issued ratings for Fulcrum Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 1 has given a sell rating, 6 have given a hold rating, and 3 have given a buy rating for FULC.

Consensus Price Target

$9.33
181.12% Upside
According to the 10 analysts' twelve-month price targets for Fulcrum Therapeutics, the average price target is $9.33. The highest price target for FULC is $23.00, while the lowest price target for FULC is $2.00. The average price target represents a forecasted upside of 181.12% from the current price of $3.32.
Get the Latest News and Ratings for FULC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Fulcrum Therapeutics and its competitors.

Sign Up

FULC Analyst Ratings Over Time

TypeCurrent Forecast
11/7/23 to 11/6/24
1 Month Ago
10/8/23 to 10/7/24
3 Months Ago
8/9/23 to 8/8/24
1 Year Ago
11/7/22 to 11/7/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
0 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$9.33$9.33$15.57$11.50
Forecasted Upside181.12% Upside161.44% Upside73.98% Upside168.07% Upside
Consensus Rating
Hold
Hold
Buy
Hold

FULC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FULC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Fulcrum Therapeutics Stock vs. The Competition

TypeFulcrum TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.79
2.50
Consensus RatingHoldModerate BuyHold
Predicted Upside181.12% Upside18,463.34% Upside9.47% Upside
News Sentiment Rating
Very Positive News

See Recent FULC News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/13/2024HC Wainwright
2 of 5 stars
A. Fein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$17.00 ➝ $4.00+16.28%
9/12/2024Leerink Partnrs
5 of 5 stars
J. Schwartz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/12/2024Royal Bank of Canada
4 of 5 stars
G. Renza
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$15.00 ➝ $4.00+13.96%
9/12/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$4.00+13.64%
9/12/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$10.00 ➝ $2.00-41.86%
9/12/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$22.00 ➝ $3.00-12.79%
9/12/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Kluska
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
5/14/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$16.00 ➝ $14.00+90.48%
5/13/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$6.00 ➝ $15.00+104.08%
2/28/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$13.00 ➝ $15.00+40.58%
3/10/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$8.00 ➝ $7.00+52.17%
3/10/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$18.00 ➝ $10.00+121.73%
3/10/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$11.00 ➝ $8.00+65.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:16 AM ET.


FULC Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Fulcrum Therapeutics is $9.33, with a high forecast of $23.00 and a low forecast of $2.00.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There is currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FULC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FULC, but not buy additional shares or sell existing shares.

According to analysts, Fulcrum Therapeutics's stock has a predicted upside of 181.12% based on their 12-month stock forecasts.

Over the previous 90 days, Fulcrum Therapeutics's stock had 6 downgrades and 1 upgrade by analysts.

Fulcrum Therapeutics has been rated by research analysts at Bank of America, Cantor Fitzgerald, HC Wainwright, Leerink Partners, Leerink Partnrs, Royal Bank of Canada, and Stifel Nicolaus in the past 90 days.

Analysts like Fulcrum Therapeutics less than other "medical" companies. The consensus rating for Fulcrum Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FULC compares to other companies.


This page (NASDAQ:FULC) was last updated on 11/6/2024 by MarketBeat.com Staff
From Our Partners